Novel Risk Score for 30-Day Adverse Events Following Colonoscopy in Older Adults.

IF 3.4 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Gut and Liver Pub Date : 2025-04-21 DOI:10.5009/gnl250010
Min-Jae Kim, Seoyoon Choi, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim, Yuna Kim, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park, Jaeyoung Chun
{"title":"Novel Risk Score for 30-Day Adverse Events Following Colonoscopy in Older Adults.","authors":"Min-Jae Kim, Seoyoon Choi, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim, Yuna Kim, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park, Jaeyoung Chun","doi":"10.5009/gnl250010","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aims: </strong>Physicians are challenged with balancing benefits and risks of performing colonoscopies in older adults. We identified adverse event risk factors in this population and developed a predictive risk score for colonoscopy-related adverse events.</p><p><strong>Methods: </strong>From August 2017 to August 2022, 8,154 patients aged ≥60 years who underwent screening or diagnostic colonoscopies were enrolled at Gangnam Severance Hospital. The primary outcome was 30-day adverse events, defined as emergency room visits or unplanned hospitalizations post-colonoscopy. The frailty index calculated via laboratory findings (FI-LAB) was derived from blood test results and vital signs. A risk score was developed and categorized to predict colonoscopy-related adverse events. Data from 9,154 colonoscopies from September 2022 to December 2023 at two tertiary referral hospitals were used for internal and external validation.</p><p><strong>Results: </strong>The mean age was 67.9 years (range, 60 to 94 years). The 30-day adverse event rate was 1.4%. Adverse events were independently associated with the use of aspirin (adjusted odds ratio [aOR], 2.24), P2Y12 inhibitors (aOR, 1.79), and anticoagulants (aOR, 2.47) and with moderate (aOR, 4.54) and high (aOR, 11.40) FI-LABs. The incidence of adverse events in the low-, moderate-, and high-risk groups were 0.3%, 2.2%, and 10.7%, respectively (p<0.001). The area under the receiver operating characteristic curve for the risk scores were 0.821, 0.856, and 0.757 for the derivation, internal, and external cohorts, respectively.</p><p><strong>Conclusions: </strong>Colonoscopy-related adverse events in older adults were linked to frailty and medication use and were not dependent on age. This novel risk score supports personalized decision-making when performing colonoscopies in older adults.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut and Liver","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5009/gnl250010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aims: Physicians are challenged with balancing benefits and risks of performing colonoscopies in older adults. We identified adverse event risk factors in this population and developed a predictive risk score for colonoscopy-related adverse events.

Methods: From August 2017 to August 2022, 8,154 patients aged ≥60 years who underwent screening or diagnostic colonoscopies were enrolled at Gangnam Severance Hospital. The primary outcome was 30-day adverse events, defined as emergency room visits or unplanned hospitalizations post-colonoscopy. The frailty index calculated via laboratory findings (FI-LAB) was derived from blood test results and vital signs. A risk score was developed and categorized to predict colonoscopy-related adverse events. Data from 9,154 colonoscopies from September 2022 to December 2023 at two tertiary referral hospitals were used for internal and external validation.

Results: The mean age was 67.9 years (range, 60 to 94 years). The 30-day adverse event rate was 1.4%. Adverse events were independently associated with the use of aspirin (adjusted odds ratio [aOR], 2.24), P2Y12 inhibitors (aOR, 1.79), and anticoagulants (aOR, 2.47) and with moderate (aOR, 4.54) and high (aOR, 11.40) FI-LABs. The incidence of adverse events in the low-, moderate-, and high-risk groups were 0.3%, 2.2%, and 10.7%, respectively (p<0.001). The area under the receiver operating characteristic curve for the risk scores were 0.821, 0.856, and 0.757 for the derivation, internal, and external cohorts, respectively.

Conclusions: Colonoscopy-related adverse events in older adults were linked to frailty and medication use and were not dependent on age. This novel risk score supports personalized decision-making when performing colonoscopies in older adults.

老年人结肠镜检查后30天不良事件的新风险评分。
背景/目的:医生面临着平衡老年人结肠镜检查的益处和风险的挑战。我们确定了该人群的不良事件风险因素,并制定了结肠镜相关不良事件的预测风险评分。方法:2017年8月至2022年8月,在江南Severance医院接受筛查或诊断性结肠镜检查的年龄≥60岁的8154例患者入组。主要终点是30天的不良事件,定义为急诊就诊或结肠镜检查后意外住院。虚弱指数通过实验室检查结果(FI-LAB)计算,由血液检查结果和生命体征得出。制定了风险评分并进行分类,以预测结肠镜检查相关的不良事件。从2022年9月至2023年12月在两家三级转诊医院进行的9154例结肠镜检查数据用于内部和外部验证。结果:患者平均年龄67.9岁(60 ~ 94岁)。30天不良事件发生率为1.4%。不良事件与阿司匹林(校正优势比[aOR], 2.24)、P2Y12抑制剂(aOR, 1.79)和抗凝剂(aOR, 2.47)的使用以及中度(aOR, 4.54)和高(aOR, 11.40) FI-LABs独立相关。低、中、高风险组的不良事件发生率分别为0.3%、2.2%和10.7%(结论:老年人结肠镜相关不良事件与虚弱和用药有关,不依赖于年龄。)这种新颖的风险评分支持老年人进行结肠镜检查时的个性化决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gut and Liver
Gut and Liver 医学-胃肠肝病学
CiteScore
7.50
自引率
8.80%
发文量
119
审稿时长
6-12 weeks
期刊介绍: Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut and Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. Gut and Liver is jointly owned and operated by 8 affiliated societies in the field of gastroenterology, namely: the Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, the Korean College of Helicobacter and Upper Gastrointestinal Research, the Korean Association for the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, the Korean Pancreatobiliary Association, and the Korean Society of Gastrointestinal Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信